AstraZeneca Stock Price Prediction 2025, 2026, 2030, 2040, 2050

AstraZeneca PLC is a Swedish-British multinational biotechnology and pharmaceutical corporation in Cambridge, United Kingdom. It was established in 1992 following the merger between Sweden’s Astra AB and the UK’s Zeneca Group; AstraZeneca focuses on developing, discovering, and commercializing prescription drugs.

This blog will provide a detailed analysis of its AstraZeneca stock price predictions as far as 25 years from now (2025 – 2050).

What is AstraZeneca PLC NYSE: AZN?

AstraZeneca Plc is a company dedicated to researching, developing, manufacturing, and commercializing prescription medicines. The company specializes in treatment for various therapeutic areas, including oncology, gastrointestinal, cardiovascular neurology, respiratory and inflammation. Its most well-known items include Tagrisso, Imfinzi, Lynparza, Calquence, and Farxiga. AstraZeneca operates worldwide, providing patients and healthcare professionals across several continents.

Fundamental Data

Metric	Value
Market Cap	$218.49B
Enterprise Value	$245.13B
Trailing P/E	34.10
Forward P/E	15.50
PEG Ratio (5yr expected)	0.78
Price/Sales	4.32
Price/Book	5.39
Profit Margin	12.68%
Operating Margin (ttm)	20.40%
Revenue (ttm)	$51.21B
Gross Profit (ttm)	$42.3B
EBITDA	$18.39B
Net Income (ttm)	$6.5B
Diluted EPS (ttm)	$2.07
Total Cash (mrq)	$4.93B
Total Debt (mrq)	$31.61B
Debt/Equity Ratio	77.47%
Operating Cash Flow (ttm)	$11.33B
Levered Free Cash Flow (ttm)	$9.51B
Beta (5Y Monthly)	0.18
52-Week High	$87.68
52-Week Low	$60.47
Annual Dividend Rate	$1.49
Dividend Yield	2.10%
Payout Ratio	71.57%

Peer Comparisons

Company	Current Price ($)	Market Cap ($M)	PE TTM	ROE (%)	Revenue (Qtr $M)	Net Profit (Qtr $M)
AstraZeneca PLC – ADR	70.76	219,433.3	33.79	15.63	13,565	1,429
Eli Lilly & Co	811.08	729,416.97	87.15	48.93	11,439.1	970.3
Novo Nordisk – ADR	84.45	374,927.11	28.4	88.07	71,311	27,301
Johnson & Johnson	152.15	366,319.83	26.04	–	22,520	3,431
AbbVie Inc	183.9	324,977.1	63.45	34.91	14,460	1,561
Merck & Co Inc	98.82	249,978.59	20.58	0.87	16,657	3,157
Novartis AG – ADR	104.72	206,831.35	11.89	28.02	13,172	3,189

AstraZeneca Stock Price History

Period	Stock Price (USD)
1 Year Ago	$65.52
6 Months Ago	$87.62
5 Years Ago	$54.51
All-Time High	$87.62

AstraZeneca Stock Price Today

AstraZeneca Stock Price Prediction Tomorrow

Day	Minimum Price ($)	Maximum Price ($)
Tomorrow	-$2.5	+$4.1

AZN Indicator Based Technical Analysis

NOTE!
Signals may differ across timeframes. If you’re planning to purchase AZN and keep it for more than one week, it’s suggested that you choose signals from weekly and daily timeframes. For trading in the short term, signals that range from 5 minutes to 1-hour timeframes are better appropriate.

AstraZeneca Stock Price Prediction 2025

In 2025, AstraZeneca expects a steady rise in its stock prices due to strategic investments and robust R&D. The company’s emphasis on therapeutic areas with high impact, like cancer treatment or rare ailments, will lead to revenue growth. Innovative research and smart acquisitions help to support growth in value and increase its market share globally.

Our analysis shows that the stock price is expected to be between $55 and $120.

Year	Minimum Target ($)	Maximum Target ($)
2025	$55	$120

Month	Minimum Target ($)	Maximum Target ($)
January	$55	$60
February	$57	$65
March	$60	$70
April	$62	$75
May	$65	$80
June	$68	$85
July	$70	$90
August	$75	$95
September	$78	$100
October	$80	$105
November	$85	$110
December	$90	$120

AstraZeneca Stock Price Prediction 2026

In 2026, AstraZeneca’s share price forecast remains optimistic as the company continues to invest in innovations in medication development. Its investment in gene-based therapies, personalized medicine, and AI-driven development drives its growth. Expanding into emerging markets enhances revenue growth, positioning the pharmaceutical industry as a leading innovator in sustainable healthcare solutions.

Our analysis shows that the stock price is expected to be between $80 and $155.

Year	Minimum Target ($)	Maximum Target ($)
2026	$80	$155

Month	Minimum Target ($)	Maximum Target ($)
January	$80	$90
February	$85	$95
March	$90	$100
April	$95	$110
May	$100	$115
June	$105	$120
July	$110	$125
August	$115	$130
September	$120	$135
October	$125	$140
November	$130	$145
December	$140	$155

AstraZeneca Stock Price Prediction 2030

AstraZeneca’s 2030 stock price forecast is expected to be a boon thanks to the breakthroughs in cell therapies and antibody-drug conjugates. The pipeline for late-stage treatments and quantum computing-aided drug discovery will fuel the company’s revenue growth. Precision medicine and smart acquisitions further make the company an innovator in next-generation therapies worldwide.

Our analysis shows that the stock price is expected to be between $320 and $450.

Year	Minimum Target ($)	Maximum Target ($)
2030	$320	$450

Month	Minimum Target ($)	Maximum Target ($)
January	$320	$340
February	$330	$350
March	$340	$360
April	$350	$370
May	$360	$380
June	$370	$390
July	$380	$400
August	$390	$410
September	$400	$420
October	$410	$430
November	$420	$440
December	$430	$450

AstraZeneca Stock Price Prediction 2040

In 2040, AstraZeneca’s price forecast remains optimistic because innovation in research into therapeutics is the key to expansion. Strategic investment in AI-driven platforms for research and quantum computing-based drug development aids the development of revolutionary cancer treatments and rare disease solutions. Expanding into emerging markets boosts revenue growth and increases global competitiveness. Amazingly robust.

Our analysis shows that the stock price is expected to be between $1150 and $1350.

Year	Minimum Target ($)	Maximum Target ($)
2040	$1,150	$1,350

Month	Minimum Target ($)	Maximum Target ($)
January	$1,150	$1,170
February	$1,170	$1,190
March	$1,190	$1,210
April	$1,210	$1,230
May	$1,220	$1,240
June	$1,230	$1,250
July	$1,240	$1,260
August	$1,250	$1,270
September	$1,260	$1,280
October	$1,270	$1,300
November	$1,290	$1,320
December	$1,300	$1,350

AstraZeneca Stock Price Prediction 2050

Looking forward to 2050, AstraZeneca’s price forecast is very positive since the company is a pioneer in personalized therapies and gene therapy. Focusing on innovative biotechnology acquisitions and next-generation treatments generates robust revenue growth. With sustainable solutions to healthcare and clever acquisitions, the pharmaceutical industry is poised for an increase in value over the long term, with global flourishing.

Our analysis shows that the stock price is expected to be between $1850 and $2250.

Year	Minimum Target ($)	Maximum Target ($)
2050	$1,850	$2,250

Month	Minimum Target ($)	Maximum Target ($)
January	$1,850	$1,900
February	$1,880	$1,930
March	$1,910	$1,960
April	$1,940	$2,000
May	$1,970	$2,030
June	$2,000	$2,070
July	$2,030	$2,100
August	$2,060	$2,130
September	$2,090	$2,160
October	$2,120	$2,190
November	$2,150	$2,220
December	$2,200	$2,250

AstraZeneca Stock Price Forecast

Year	Minimum Target ($)	Maximum Target ($)
2025	$55	$120
2026	$80	$155
2030	$320	$450
2040	$1,150	$1,350
2050	$1,850	$2,250

AstraZeneca Stock Ownership Pattern

Investor Type	Percentage (%)
Mutual Funds	12.5%
Other Institutional Investors	16%
ETFs	0.85%
Public Companies and Individual Investors	70.65%

Abbott Laboratories Stock Price Prediction 2025, 2026, 2030, 2040, 2050

Should I Buy AstraZeneca PLC Stock?

AstraZeneca has many individuals who own its shares, comprising almost 70.65%. Mutual funds control around 12.5%, while other Institutional funds, such as ETFs, have smaller shares. This indicates a strong interest from the public. AstraZeneca could be a worthwhile investment if you’re searching for an organization that is widely supported.

AstraZeneca Stock Earning Results(USD)

All financials are is in USD Million and price data in USD

Indicator	Sep ’24	Jun ’24	Mar ’24	Dec ’23	Sep ’23	Jun ’23	Mar ’23
Operating Revenue	13,565	12,938	12,679	12,024	11,492	11,416	10,879
Cost of Revenue	3,081	2,183	2,218	2,308	2,095	1,960	1,905
Gross Profit	10,484	10,755	10,461	9,716	9,397	9,456	8,974
Operating Expenses	8,378	8,009	7,346	7,712	7,443	7,000	6,666
Operating Profit	2,106	2,746	3,115	2,004	1,954	2,456	2,308
Profit Before Tax	1,828	2,397	2,800	897	1,652	2,088	2,262
Tax	395	469	620	-62	274	268	458
Net Income Common Stockholders	1,429	1,927	2,179	960	1,374	1,818	1,803
Basic EPS	0.5	0.6	0.7	0.3	0.4	0.6	0.6
Number of Shares End	3,100	3,100	3,098	3,098	3,098	3,100	3,098
Net Income Cont./Disc. Operations	1,429	1,927	2,179	960	1,374	1,818	1,803
Normalized Income	1,429	1,927	2,179	1,551.3	1,374	1,818	1,610.2
Interest Income	183	100	111	65	101	64	78
Interest	457	443	413	408	392	431	365
Net Interest Income	-274	-343	-302	-343	-291	-367	-287
EBIT	2,285	2,840	3,213	1,305	2,044	2,519	2,627
EBITDA	4,102	4,119	4,468	2,179	3,326	3,795	4,129
Reconciled Cost of Revenue	3,081	2,183	2,218	2,308	2,095	1,960	1,905
Reconciled Depreciation	1,817	1,279	1,255	874	1,282	1,276	1,502
Profit from Continuing Operations	1,828	2,397	2,800	897	1,652	2,088	2,262
Normalized EBITDA	4,102	4,119	4,468	2,909	3,326	3,795	3,888

Expert Prediction On the Future Of AstraZeneca

AstraZeneca’s most recent financials have shown a steady increase in revenue, ranging from $10,879 million on Mar 23 to $13,565 million on Sep 24. Operating profit increased; however, tax and other expenses damage net income. EPS remains constant. Experts anticipate strong growth in the future because of the advancements in pharmaceuticals and an increasing demand for global healthcare.

Is AstraZeneca Stock to Good Buy? (Bull vs. Bear Case)

Bullish Case:

• Significant revenue and profit growth.
• Leading to cancer, vaccines, and rare diseases.
• Growing demand for medicines.
• Intense research and new drug pipeline.

Bearish Case:

• High costs and debt.
• Competition from other companies.
• Patent expirations risk.
• The stock prices may be high.

Conclusion

AstraZeneca is experiencing significant growth, with high demand for its medicines and a robust research pipeline. However, rising drug costs, competition, and the risk of patent infringement pose a challenge. Investors should weigh the company’s potential and strengths against the risks. If you believe in the company’s innovative strength, this could be a wise investment despite the short-term uncertainties.

FAQs